Pediatric advisory committee considers heartburn drugs
This article was originally published in The Tan Sheet
Executive Summary
FDA's Pediatric Advisory Committee will meet June 21 in Bethesda, Md., to discuss pediatric safety reviews for several drugs, including proton pump inhibitors Prevacid (lansoprazole) and Prilosec (omeprazole), according to a May 11 Federal Register notice. The notice does not specify if the drugs could be available to children in the future, but currently both products are recommended for patients 18 years and older. Comments are due June 7